Gynecologic Cancers

Cross-cancer immunotherapy analyses revealed that MTFR1 exhibited improved predictive performance for anti-PD-1 response during the on-treatment phase compared with pretreatment settings. This study elucidates the multidimensional role of MTFR1 as a putative oncogene in BRCA, highlighting it as a promising prognostic biomarker and therapeutic target.

However, CD68-based assessment alone showed no significant association with clinicopathological parameters in our study. Hence, further studies with a larger sample size and additional markers are recommended.

Particular attention is given to HER2-directed antibody-drug conjugates, especially trastuzumab deruxtecan (T-DXd), which have emerged as an important recent therapeutic advance and have renewed interest in HER2 as an actionable target in selected patients with HER2-expressing cervical carcinoma. This review further highlights the need for biomarker-driven patient selection, standardized HER2 assessment, and rational integration of HER2-directed strategies into precision treatment for CC.

In peri-tumour specimens C-reactive protein immune expression was significantly higher than in lichen sclerosus specimens. No statistically significant differences were found between intratumour and lichen sclerosus specimens. No statistically significant difference between each type of specimens acquired in the group of patients diagnosed with lichen sclerosus and the specimens acquired in the group of patients diagnosed with vulvar cancer regarding Lysophosphatidic Acid immune expression was detected.

Furthermore, we propose translational strategies for precision application: LKB1/PTEN status-based patient stratification, innovative combinations with CDK4/6 inhibitors, mTOR inhibitors, and immune checkpoint inhibitors, and clinical pathway optimization. By bridging metabolic endocrinology and gynecologic oncology, the available data provide preliminary theoretical basis to explore future shift of metformin from empirical off-label reuse toward biomarker-guided individualized medication, which still needs large-scale prospective validation.

Mean NfL levels increased from 2.32 at baseline (median 2.16) to 3.28 at mid-chemotherapy (median 3.47) and remained elevated at the follow-up visit (mean 3.85; median 4.38). Higher NfL levels were associated with worse FACT-GOG-NTx scores during chemotherapy (r = -0.32, p ≤ 0.01) and after chemotherapy (r = -0.31, p < 0.01). NfL increased throughout treatment and was associated with patient reported CIPN symptoms, supporting its potential as an objective biomarker for early detection and monitoring of chemotherapy-induced peripheral neuropathy in adolescents and young adults receiving neurotoxic chemotherapy.

Perceived risk was intertwined with cancer worry, and individuals made decisions regarding RRSO based on factors such as perceived risk, control, family planning, hormonal impacts, and recovery. Importantly, healthcare providers exerted both direct and indirect influences on the decision-making process.

P2, N=50, Suspended, University of Utah | Recruiting --> Suspended

Our study supports the prognostic relevance of both sentinel lymph node assessment and molecular classification in early-stage endometrial cancer, with potential implications for post-operative risk stratification and management.

Nevertheless, clinical translation remains challenged by response heterogeneity attributable to tumor heterogeneity, the emergence of resistance mechanisms, and class-specific adverse events including ocular toxicity, interstitial lung disease (ILD), hepatotoxicity, and peripheral neuropathy. Continued refinement of next-generation ADC platforms - encompassing bispecific ADCs, dual-payload ADCs, peptide-drug conjugates (PDCs), and radionuclide-conjugated drugs - is anticipated to overcome current limitations and deliver superior oncologic outcomes.

These findings underscore the potential of autophagy as a therapeutic target and highlight strategies for combining autophagy modulators with conventional treatments to overcome resistance. This article provides a foundation for the development of precision medicine approaches tailored to autophagy-related pathways in gynaecologic malignancies.

These findings highlight important molecular features of EC in Kurdish patients and may support future development of targeted therapeutic strategies. Further validation with larger cohorts is recommended.